GT Biopharma, Inc. (GTBP)
0.45
-0.02
(-4.26%)
USD |
NASDAQ |
Mar 06, 16:00
0.45
0.00 (0.00%)
After-Hours: 20:00
GT Biopharma Cash from Investing (Quarterly) : 0.00 for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Lyell Immunopharma, Inc. | 3.349M |
| Regeneron Pharmaceuticals, Inc. | 220.30M |
| SELLAS Life Sciences Group, Inc. | 0.00 |
| Crinetics Pharmaceuticals, Inc. | 57.11M |
| Sutro Biopharma, Inc. | 39.99M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -4.021M |
| Cash from Financing (Quarterly) | 8.305M |
| Free Cash Flow | -12.91M |
| Free Cash Flow Per Share (Quarterly) | -0.6141 |
| Free Cash Flow to Equity (Quarterly) | -4.021M |
| Free Cash Flow to Firm (Quarterly) | -3.894M |
| Free Cash Flow Yield | -735.6% |